Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indices Standalone Sandoz committed to extend leadership in ...

Earlier on August 25, 2022, Novartis revealed its intention to separate Sandoz, the generics and biosimilars division, into an independent publicly traded company through a 100% spin-off.

Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on Oct. 4. This follows the ...

Sandoz is one of the largest off-patent pharmaceutical manufacturers in the world. It generates roughly 75% of sales from generic drugs and the remainder from biosimilars and it has a significant ...